Immucell (ICCC) Q2 2026 Earnings Report

The call highlighted meaningful commercial momentum: double-digit product revenue growth (Q2 +11.5%, H1 +20.9%), strong U.S. performance and expanding market share, improved profitability and adjusted EBITDA, and a clearly defined multi‑phase capacity expansion to more than triple production capacity. Offsetting these positives were significant gross margin pressure driven by lower manufacturing output, a recurring cost shift from the discontinued Re-Tain program into COGS, a one-time scrap event (~$150K), and a sharp decline in international sales (–38.9% in Q2). Management presented concrete mitigation steps (yield improvement initiatives, capacity investments, colostrum sourcing programs) and expects to finance most expansion with cash on hand. Overall, the positives (revenue, profitability, working capital strength, and actionable expansion plans) appear to outweigh the operational and margin headwinds, though execution risk remains on manufacturing yields and international ramp.

Guidance from the call focused on materially expanding and de‑risking supply while improving costs and yields: management plans an ~ $8.0M, two‑phase capacity program (a $3.5M freeze‑drying phase to be completed in H1 2027 and ~ $4.5M liquids phase targeted by year‑end 2027) that it expects will more than triple current capacity, shorten processing time from 2–3 months to under 1 month, and improve long‑term product cost; the company is on track to produce nearly 1.0 million more manufacturing units in 2026 versus 2025, financing the majority with cash on hand ($8.9M as of 6/30/26) and operating cash (may use credit line), while continuing yield work (colostrum is ~50% of product cost). Recent operating/financial context cited with that guidance: Q1 production exceeded 450,000 units/month and Q2 averaged ~350,000 units/month (seasonal/planned), Q2 product sales $7.2M (+11.5% YoY) and H1 product sales $17.5M (+20.9% YoY), gross margin 33.9% (vs 43.7% LY) with an 11.1‑point sequential decline driven ~7.5 points by lower output, 2.1 points by ~$150k scrap and 1.9 points by the Re‑Tain cost shift, adjusted EBITDA of $2.7M in Q2 and $5.4M for H1 (both include a $2M legal settlement), net income of $1.8M ($0.20/share) in Q2 and $3.8M for H1, inventory $9.1M and working capital $16.6M, distributor out‑the‑door volumes +21% Q1 / +28% Q2 (24% H1), and U.S. market share for First Defense rising from ~15% in Dec‑2025 to ~19% in June‑2026 (share of spend ~29% to ~38%).